Changes to Genomic Sequencing Procedures (GSP) and Other Molecular Multianalyte Assays (February 2024)

Why This Topic Matters

The update affects how molecular oncology and related sequencing services are organized and reported in CPT 2024. Understanding the changes helps readers recognize the revised structure of the code family and the general categories of testing addressed in the update.

Article Sections

1. February 2024 page 8

   Introductory context for the February 2024 CPT update and the scope of the article.

2. Genomic Sequencing Procedures and Other Molecular Multianalyte Assays

   General background on genomic sequencing procedures, molecular multianalyte assays, specimen types, and related terminology used in the updated CPT section.

3. Definitions

   Definitions of key technical terms and testing concepts referenced throughout the article.

4. CPT code revisions and new code families

   Summary of the revised and newly established CPT code families, including the broad testing categories they address.

5. Table 1. Differences Between GSP Analysis of Tumor Tissue and Cell-Free Nucleic Acid Specimen Codes

   Comparison of the major components associated with tumor-tissue and cell-free nucleic acid testing pathways in the updated code families.

6. Clinical examples and procedural descriptions

   Illustrative scenarios and procedural overviews showing the types of testing contexts discussed in the article.